Polterauer Stephan, Grimm Christoph, Mustea Alexander, Concin Nicole, Tanner Berno, Thiel Falk, Heinze Georg, Reinthaller Alexander, Zeillinger Robert, Hefler Lukas A
Department of Obstetrics and Gynecology, Medical University of Vienna, A-1090 Vienna, Währinger Gürtel 18-20, Austria.
Gynecol Oncol. 2007 May;105(2):385-9. doi: 10.1016/j.ygyno.2006.12.021. Epub 2007 Feb 6.
Polymorphisms within the vascular endothelial growth factor (VEGF) gene, the most important regulator of angiogenesis and vascular permeability, were shown to be independently associated with an impaired prognosis in various malignancies. No data have been reported in ovarian cancer.
In the present multi-center study, we examined three common polymorphisms within the VEGF gene (VEGF +405G/C, VEGF -460C/T, and VEGF +936C/T) in 553 Caucasian patients with ovarian cancer using pyrosequencing.
The three investigated polymorphisms did not correlate with any of the investigated clinico-pathological parameters. In univariate and multivariate models, only FIGO stage and patient's age at diagnosis, but not any polymorphism or any haplotype were correlated with patients' overall survival.
In our large multi-center study, the investigated VEGF gene polymorphisms were not associated with prognosis in patients with ovarian cancer.
血管内皮生长因子（VEGF）基因是血管生成和血管通透性的最重要调节因子，其多态性已被证明与多种恶性肿瘤的预后受损独立相关。卵巢癌方面尚无相关数据报道。
在本多中心研究中，我们采用焦磷酸测序法检测了553例白种人卵巢癌患者VEGF基因内的三种常见多态性（VEGF +405G/C、VEGF -460C/T和VEGF +936C/T）。
所研究的三种多态性与任何所研究的临床病理参数均无相关性。在单变量和多变量模型中，仅国际妇产科联盟（FIGO）分期和患者诊断时的年龄与患者的总生存期相关，而任何多态性或单倍型均无此相关性。
在我们这项大型多中心研究中，所研究的VEGF基因多态性与卵巢癌患者的预后无关。
